Bristol-Myers Squibb Company BMY announced that the FDA has accepted and granted priority review designation to a supplemental Biologics License Application (sBLA) for the label expansion of Opdivo ...
SYDNEY--(BUSINESS WIRE)--NeuClone Pharmaceuticals Ltd (NeuClone), a clinical-stage biopharmaceutical company developing high-quality biosimilar products, today disclosed two additional biosimilars in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback